Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung CancerLecia V. Sequist, D. Ross Camidge, Heather A. Wakelee et al.|New England Journal of Medicine|2015Cited by 664
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAdam J. Schoenfeld, Matthew D. Hellmann, Kathryn C. Arbour et al.|Annals of Oncology|2019Cited by 413
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369